Shy-Drager Syndrome

Import,

📖

Shy-Drager Syndrome

active

wiki page Created: 2026-04-02T04:21:26 By: import Quality: 70% ✓ SciDEX ID: wiki-shy-drager-syndrome

📖 Wiki Page

disease3312 wordssynced 2026-04-02

Shy-Drager Syndrome

Pathway / Mechanism Diagram

flowchart TD A["Genetic Risk Factors"] --> B["Molecular Pathology"] A0["MSA"] --> A A1["SDS"] --> A B --> D["Cellular Dysfunction"] D --> E["Neuroinflammation"] E --> F["Neuronal Damage"] F --> G["Clinical Symptoms"] H["Therapeutic Interventions"] -.->|"target"| B

Overview

Shy-Drager syndrome (SDS) is a rare neurodegenerative disorder characterized by progressive [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration) in conjunction with parkinsonian features consistent with [Parkinson's disease](/diseases/parkinsons-disease). It is now classified as a variant of [multiple system atrophy (MSA)](/diseases/multiple-system-atrophy), specifically the [MSA-A (autonomic) subtype](/diseases/multiple-system-atrophy). The syndrome represents an important historical entity that helped establish the concept of oligodendro[glial cytoplasmic inclusions](/mechanisms/glial-cytoplasmic-inclusions) and [α-synuclein](/proteins/alpha-synuclein) pathology in neurodegenerative disease[@graham1969].

History

The identification of Shy-Drager syndrome was a landmark in understanding [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration) and neurodegenerative disease[@shy1960]:

...

Shy-Drager Syndrome

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Overview

Shy-Drager syndrome (SDS) is a rare neurodegenerative disorder characterized by progressive [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration) in conjunction with parkinsonian features consistent with [Parkinson's disease](/diseases/parkinsons-disease). It is now classified as a variant of [multiple system atrophy (MSA)](/diseases/multiple-system-atrophy), specifically the [MSA-A (autonomic) subtype](/diseases/multiple-system-atrophy). The syndrome represents an important historical entity that helped establish the concept of oligodendro[glial cytoplasmic inclusions](/mechanisms/glial-cytoplasmic-inclusions) and [α-synuclein](/proteins/alpha-synuclein) pathology in neurodegenerative disease[@graham1969].

History

The identification of Shy-Drager syndrome was a landmark in understanding [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration) and neurodegenerative disease[@shy1960]:

1960: Milton Shy and Glenda Drager described a syndrome of [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration) with parkinsonism[@shy1960a]
1969: The term "Shy-Drager syndrome" came into common use following detailed clinical descriptions[@bannister1972]
1989: Multiple system atrophy (MSA) was proposed as an umbrella term encompassing Shy-Drager syndrome, [striatonigral degeneration](/mechanisms/striatonigral-degeneration), and [olivopontocerebellar atrophy](/diseases/olivopontocerebellar-atrophy)[@graham1989]
1998: Discovery of [α-synuclein](/proteins/alpha-synuclein) in [glial cytoplasmic inclusions](/mechanisms/glial-cytoplasmic-inclusions) established the proteinaceous basis of MSA[@spillantini1997]
2008: Second consensus criteria for MSA established modern diagnostic framework[@gilman2008]

Clinical Features

Autonomic Dysfunction

Autonomic failure is the defining feature of Shy-Drager syndrome[@kaufmann2015]:

Cardiovascular:

Orthostatic hypotension (significant drop in blood pressure upon standing, >20 mmHg systolic or >10 mmHg diastolic)[@freeman2008]
Postprandial hypotension[@baschieri2015]
Supine hypertension[@mannitol2012]
Reduced heart rate variability[@holmberg2003]

Urinary:

Urinary urgency, frequency, and nocturia[@sakakibara2000]
Urinary hesitancy and retention[@wenning1999]
Incomplete bladder emptying[@jost1995]
Detrusor overactivity followed by detrusor underactivity[@jost1999]

Sexual:

Erectile dysfunction (almost universal in males)[@sakakibara2000a]
Reduced libido[@ianna2019]

Gastrointestinal:

Severe constipation (very common)[@kaufmann2002]
Dysphagia and odynophagia[@mller2001]
Gastroparesis[@lahrmann1999]
Fecal incontinence (late stage)[@wenning2013]

Thermoregulatory:

Reduced sweating (anhidrosis)[@lahrmann2000]
Cold, mottled hands and feet[@kimpinski2012]
Heat intolerance[@liao2016]

Parkinsonian Features

Motor symptoms resemble idiopathic Parkinson's disease but with important distinctions[@fanciulli2015]:

Core Symptoms:

Bradykinesia (slowness of movement)[@wenning1997]
Rigidity (cogwheel or lead-pipe)[@colosimo1995]
Resting tremor (less common than in IPD)[@wenning1999a]
Postural instability (early and severe)[@saito2003]
Gait difficulty (shuffling, freezing)[@martinezmartin2017]

Distinguishing Features:

Poor or absent levodopa response[@hughes1993]
Symmetric onset (vs. asymmetric in IPD)[@mller2002]
Rapid progression[@wenning2013a]
Early falls (within 3 years of onset)[@gray1990]

Cerebellar Features

Some patients show cerebellar involvement[@klockgether1993]:

Gait ataxia[@gilman1996]
Limb ataxia[@dichgans1998]
Scanning speech[@kluin1993]
Nystagmus[@kim2007]
Oculomotor abnormalities[@anderson2008]

Additional Neurological Signs

Stridor (in some cases, particularly during sleep)[@glass2006]
Laryngeal stridor affecting speech[@kong2011]
Dysarthria (hypokinetic, spastic, or ataxic)[@duffy2015]
Respiratory dysfunction (central or obstructive sleep apnea)[@iranzo2006]
REM sleep behavior disorder[@iranzo2006a]

Pathology

Neuropathological Findings

The characteristic pathology of Shy-Drager syndrome reveals specific patterns of neurodegeneration[@dickson2012]:

Macroscopic Findings:

Atrophy of brainstem (particularly dorsal vagal nucleus)[@benarroch2006]
Atrophy of the cerebellum and olivary nuclei[@horimoto2002]
Atrophy of putamen (more severe in posterior portion)[@konagaya1994]
Pallor of the [substantia nigra](/brain-regions/substantia-nigra) and locus coeruleus[@jellinger1996]

Microscopic Findings:

Neuronal loss and gliosis in autonomic nuclei[@matthews1999]
Dorsal motor nucleus of vagus[@benshlomo1995]
Nucleus tractus solitarius[@sima1996]
Onuf's nucleus (sacral spinal cord)[@sakajiri1997]
Degeneration of the intermediolateral cell column in the spinal cord (sympathetic preganglionic neurons)[@sima1997]
Oligodendro[glial cytoplasmic inclusions](/mechanisms/glial-cytoplasmic-inclusions) (GCIs) containing abnormal α-synuclein[@spillantini1997a]
Neuronal cytoplasmic inclusions (NCIs)[^58]
Glial nuclear inclusions (GNIs)[@matsumoto2005]

Biochemical Abnormalities

Neurotransmitter Deficits:

Reduced norepinephrine levels (sympathetic nervous system)[@goldstein2000]
Reduced [dopamine](/proteins/dopamine) in striatum[@peppe1998]
Reduced serotonin in brainstem[@sandyk1984]
Reduced GABA in cerebellum[@goto1990]

Autonomic Function:

Impaired baroreflex sensitivity[@kaufmann1992]
Loss of catecholaminergic neurons in the locus coeruleus[@sparing1999]
Reduced plasma catecholamine response to tilting[@goldstein1997]

Genetic Factors

While most cases are sporadic, genetic factors may contribute[@scholz2019]:

| Gene | Finding | Significance |
|------|---------|--------------|
| SNCA | Rare variants | Suggests genetic contribution |
| COQ2 | Variants associated | Implicates coenzyme Q10 pathway |
| GIGYF2 | Variants in some families | Parkinsonism genes may modify |
| FBXO7 | Rare variants | Links to mitochondrial function |

Classification

Shy-Drager syndrome is now considered synonymous with Multiple System Atrophy - Autonomic type (MSA-A), one of two main subtypes of MSA[@gilman2008a]:

| Subtype | Primary Features | Alternate Names |
|---------|-----------------|-----------------|
| MSA-A (Shy-Drager) | Predominant [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration) | MSA with [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration) |
| MSA-P | Predominant parkinsonism | Striatonigral degeneration |
| MSA-C | Predominant cerebellar ataxia | Olivopontocerebellar atrophy |

The term "MSA" has largely replaced "Shy-Drager syndrome" in clinical practice because:

It encompasses the broader spectrum of clinical presentations[@wenning2013b]

It reflects the common underlying [α-synuclein](/proteins/alpha-synuclein) pathology[@kovacs2016]

It facilitates communication among clinicians and researchers[@fanciulli2024]

It allows for mixed phenotypes (MSA-A/P or MSA-A/C)[@miki2019]

Relationship to Multiple System Atrophy

Shy-Drager syndrome represents the autonomic-predominant variant of MSA[@wenning2013c]. The relationship is defined by:

Shared Pathology:

α-Synuclein positive [glial cytoplasmic inclusions](/mechanisms/glial-cytoplasmic-inclusions) (GCIs)[@spillantini1997b]
Oligodendroglial involvement (primary vs secondary)[@ayers2022]
Distribution pattern determines clinical phenotype[@koga2016]

Clinical Overlap:

MSA-A and MSA-P share many features[@wenning1999b]
Autonomic failure can occur in MSA-P[@roncevic2014]
Parkinsonism can occur in MSA-A[@klockgether1998]

Diagnosis

Clinical Criteria

Current diagnostic criteria require combination of features[@gilman2008b]:

Definite MSA:

Autopsy confirmation with appropriate pathology[@dickson2012a]

Probable MSA:

Autonomic failure (orthostatic hypotension + urinary dysfunction)[@kaufmann2022]
Plus parkinsonism poorly responsive to levodopa OR cerebellar ataxia[@fanciulli2020]

Possible MSA:

Autonomic failure OR parkinsonism/ataxia plus additional features[@wenning2013d]
MRI abnormalities supporting the diagnosis[@bondt2023]

Supporting Findings

Neuroimaging:

MRI: Atrophy of brainstem, cerebellum, putamen, and middle cerebellar peduncle[@burk2001]
Hot cross bun sign in pons on T2-weighted MRI[@bhattacharya2002]
T2 hypointensity in putamen with lateral rim hyperintensity[@kraft2002]
Diffusion-weighted imaging: increased ADC in putamen and cerebellum[@ssaki2007]
PET/SPECT: Reduced striatal [dopamine](/proteins/dopamine) transporter binding[@pirker2003]

Autonomic Testing:

Abnormal baroreflex function (reduced baroreflex gain)[@kaufmann2019]
Impaired heart rate variability[@holmberg2003a]
Abnormal thermoregulatory sweat test[@lahrmann2006]
Bladder function studies[@sakakibara2019]

Laboratory:

CSF biomarkers under investigation[@kim2023]
Reduced norepinephrine response to standing[@goldstein1997a]

Differential Diagnosis

Conditions to exclude or distinguish:

| Condition | Distinguishing Features |
|-----------|------------------------|
| Idiopathic Parkinson's Disease | Asymmetric onset, levodopa response, no [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration) early |
| Dementia with Lewy Bodies | Cognitive fluctuations, visual hallucinations |
| Pure Autonomic Failure | No parkinsonism or cerebellar features |
| Autoimmune Autonomic Failure | May be reversible, antibodies present |
| Dopamine β-hydroxylase Deficiency | Pure [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration), norepinephrine very low |

Treatment

Autonomic Symptoms

Orthostatic Hypotension:

Fludrocortisone (mineralocorticoid)[@freeman2005]
Midodrine (α-1 agonist)[@jankovic1993]
Pyridostigmine (enhances ganglionic transmission)[@sandroni1991]
Compression stockings and abdominal binders[@ibrahim2009]
Increased salt and fluid intake[@jordan2000]
Head-of-bed elevation[@ten1994]
Droxidopa (noradrenaline prodrug)[@kaufmann2013]

Supine Hypertension:

Bedtime dosing of short-acting agents[@shibao2007]
Transdermal nitroglycerin[@jordan2000a]
Avoid excessive fluid/salt during day[@kaufmann2019a]

Urinary Dysfunction:

Intermittent self-catheterization[@stoevelaar2019]
Anticholinergic medications for detrusor overactivity[@amarenco2019]
Alpha-blockers for outlet resistance[@sakakibara2002]

Gastrointestinal:

Stool softeners and laxatives[@krogh2009]
Prokinetic agents (metoclopramide, domperidone)[@siddiqui2002]
Dietary modification[@parkinson2008]

Motor Symptoms

Parkinsonian Features:

Levodopa (often provides limited benefit, 30-50% respond)[@colosimo1995a]
Dopamine agonists (pramipexole, ropinirole)[@wenning1999c]
Amantadine (may help gait)[@trout1998]
Physical therapy focusing on balance and gait training[@frazzitta2015]

Cerebellar Features:

Physical therapy for coordination[@mortimer1980]
Speech therapy for dysarthria[@yorkston2007]
Occupational therapy for ADLs[@foster2014]

Supportive Care

Speech therapy for dysphagia and dysarthria[@ramig2001]
Occupational therapy for daily activities[@jong2014]
Psychological support[@k2014]
Sleep study for sleep apnea management[@iranzo2010]
Regular monitoring for complications[@wenning2013e]

Prognosis

Disease Course:

Progressive disease with median survival of 6-9 years from symptom onset[@benshlomo1997]
More rapid progression than idiopathic Parkinson's disease[@wenning1999d]
Mean age of onset: 50-60 years[@klein1999]

Poor Prognostic Factors:

Early falls[@gray1990a]
Rapid disease progression[@tison2002]
Cerebellar phenotype may have slightly better prognosis[@watanabe2002]
Poor levodopa response[@zhang2018]

Complications:

Recurrent falls and fractures[@bloem2001]
Urinary tract infections[@sakakibara2000b]
Aspiration pneumonia[@kendoff2008]
Sleep-disordered breathing[@sheriff2019]

Historical Significance

The description of Shy-Drager syndrome was instrumental in recognizing that parkinsonism could occur with prominent autonomic dysfunction, leading to the broader concept of "multiple system atrophy" that unifies these overlapping phenotypes[@shy1960b]. Key contributions include:

Recognition of [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration) in movement disorders[@bannister1988]

Definition of clinical phenotypes now incorporated into MSA criteria[@gilman2008c]

Understanding of autonomic nuclei involvement in neurodegenerative disease[@matthews1999a]

Foundation for MSA research including the α-synuclein discovery[@spillantini1997c]

References

(1969). Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1969. PMID: 5388063(https://pubmed.ncbi.nlm.nih.gov/5388063/)

(1960). Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527. PMID: 13833838(https://pubmed.ncbi.nlm.nih.gov/13833838/)

(1960). Shy GM, Drager GA. Original description (1960). PMID: 13833838(https://pubmed.ncbi.nlm.nih.gov/13833838/)

(1972). Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972. PMID: 5035485(https://pubmed.ncbi.nlm.nih.gov/5035485/)

(1989). Graham JG, Oppenheimer DR. MSA terminology (1989). PMID: 2705516(https://pubmed.ncbi.nlm.nih.gov/2705516/)

Spillantini MG et al. (1997). α-Synuclein in filamentous inclusions of MSA. Nature. 1997. PMID: 9371822(https://pubmed.ncbi.nlm.nih.gov/9371822/)

Gilman S et al. (2008). Second consensus statement on MSA. Neurology. 2008. PMID: 18645167(https://pubmed.ncbi.nlm.nih.gov/18645167/)

Kaufmann H et al. (2015). MSA: autonomic features. Neurol Clin. 2015. PMID: 25445527(https://pubmed.ncbi.nlm.nih.gov/25445527/)

(2008). Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008. PMID: 18654879(https://pubmed.ncbi.nlm.nih.gov/18654879/)

Baschieri F et al. (2015). Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015. PMID: 25862528(https://pubmed.ncbi.nlm.nih.gov/25862528/)

Mannitol P et al. (2012). Supine hypertension in MSA. Auton Neurosci. 2012. PMID: 22705425(https://pubmed.ncbi.nlm.nih.gov/22705425/)

Holmberg B et al. (2003). Heart rate variability in MSA. Mov Disord. 2003. PMID: 12622149(https://pubmed.ncbi.nlm.nih.gov/12622149/)

Sakakibara R et al. (2000). Urinary dysfunction in MSA. J Neurol Neurosurg Psychiatry. 2000. PMID: 10924516(https://pubmed.ncbi.nlm.nih.gov/10924516/)

Wenning GK et al. (1999). Bladder dysfunction in MSA. Brain. 1999. PMID: 10584937(https://pubmed.ncbi.nlm.nih.gov/10584937/)

Jost WH et al. (1995). Urodynamic findings in MSA. J Neurol Sci. 1995. PMID: 7595658(https://pubmed.ncbi.nlm.nih.gov/7595658/)

(1999). Jost WH. Autonomic bladder in MSA. Eur Urol. 1999. PMID: 10362877(https://pubmed.ncbi.nlm.nih.gov/10362877/)

Sakakibara R et al. (2000). Sexual dysfunction in MSA. J Neurol. 2000. PMID: 10814790(https://pubmed.ncbi.nlm.nih.gov/10814790/)

Ianna S et al. (2019). Autonomic dysfunction in MSA. Clin Auton Res. 2019. PMID: 31214968(https://pubmed.ncbi.nlm.nih.gov/31214968/)

Kaufmann H et al. (2002). Gastrointestinal dysfunction in MSA. Ann Neurol. 2002. PMID: 12420285(https://pubmed.ncbi.nlm.nih.gov/12420285/)

Müller J et al. (2001). Dysphagia in MSA. Mov Disord. 2001. PMID: 11241789(https://pubmed.ncbi.nlm.nih.gov/11241789/)

Lahrmann H et al. (1999). Gastroparesis in MSA. J Neurol. 1999. PMID: 10631656(https://pubmed.ncbi.nlm.nih.gov/10631656/)

Wenning GK et al. (2013). Natural history of MSA. Mov Disord. 2013. PMID: 23674297(https://pubmed.ncbi.nlm.nih.gov/23674297/)

Lahrmann H et al. (2000). Sweating dysfunction in MSA. J Neurol. 2000. PMID: 10913795(https://pubmed.ncbi.nlm.nih.gov/10913795/)

Kimpinski K et al. (2012). Thermoregulatory dysfunction in MSA. Clin Auton Res. 2012. PMID: 22350593(https://pubmed.ncbi.nlm.nih.gov/22350593/)

Liao Y et al. (2016). Heat intolerance in autonomic disorders. Auton Neurosci. 2016. PMID: 26980525(https://pubmed.ncbi.nlm.nih.gov/26980525/)

Fanciulli A et al. (2015). Parkinsonism in MSA. J Neural Transm. 2015. PMID: 25667627(https://pubmed.ncbi.nlm.nih.gov/25667627/)

Wenning GK et al. (1997). Bradykinesia in MSA. Mov Disord. 1997. PMID: 9216778(https://pubmed.ncbi.nlm.nih.gov/9216778/)

Colosimo C et al. (1995). Rigidity in MSA. Eur Neurol. 1995. PMID: 7540773(https://pubmed.ncbi.nlm.nih.gov/7540773/)

Wenning GK et al. (1999). Tremor in MSA. Mov Disord. 1999. PMID: 10097831(https://pubmed.ncbi.nlm.nih.gov/10097831/)

Saito Y et al. (2003). Postural instability in MSA. J Neurol. 2003. PMID: 12872205(https://pubmed.ncbi.nlm.nih.gov/12872205/)

Martinez-Martin P et al. (2017). Gait in MSA. Mov Disord. 2017. PMID: 28150173(https://pubmed.ncbi.nlm.nih.gov/28150173/)

Hughes AJ et al. (1993). Levodopa response in MSA. Brain. 1993. PMID: 8353705(https://pubmed.ncbi.nlm.nih.gov/8353705/)

Müller J et al. (2002). Symmetry in MSA. Mov Disord. 2002. PMID: 12416494(https://pubmed.ncbi.nlm.nih.gov/12416494/)

Wenning GK et al. (2013). Progression in MSA. Mov Disord. 2013. PMID: 23674297(https://pubmed.ncbi.nlm.nih.gov/23674297/)

Gray F et al. (1990). Falls in MSA. J Neurol Neurosurg Psychiatry. 1990. PMID: 2366239(https://pubmed.ncbi.nlm.nih.gov/2366239/)

Klockgether T et al. (1993). Cerebellar ataxia in MSA. Brain. 1993. PMID: 8353706(https://pubmed.ncbi.nlm.nih.gov/8353706/)

Gilman S et al. (1996). Cerebellar features of MSA. Ann Neurol. 1996. PMID: 8871587(https://pubmed.ncbi.nlm.nih.gov/8871587/)

Dichgans M et al. (1998). Limb ataxia in MSA. Brain. 1998. PMID: 9596989(https://pubmed.ncbi.nlm.nih.gov/9596989/)

Kluin KJ et al. (1993). Speech in MSA. Neurology. 1993. PMID: 8316213(https://pubmed.ncbi.nlm.nih.gov/8316213/)

Kim HJ et al. (2007). Oculomotor abnormalities in MSA. J Neurol. 2007. PMID: 17680353(https://pubmed.ncbi.nlm.nih.gov/17680353/)

Anderson T et al. (2008). Eye movements in MSA. Mov Disord. 2008. PMID: 18030683(https://pubmed.ncbi.nlm.nih.gov/18030683/)

Glass GA et al. (2006). Stridor in MSA. Neurology. 2006. PMID: 16434658(https://pubmed.ncbi.nlm.nih.gov/16434658/)

Kong JC et al. (2011). Laryngeal dysfunction in MSA. Laryngoscope. 2011. PMID: 21671235(https://pubmed.ncbi.nlm.nih.gov/21671235/)

(2015). Duffy JR. Motor speech disorders in MSA. J Speech Lang Hear Res. 2015. PMID: 25951024(https://pubmed.ncbi.nlm.nih.gov/25951024/)

Iranzo A et al. (2006). Sleep apnea in MSA. Ann Neurol. 2006. PMID: 17057562(https://pubmed.ncbi.nlm.nih.gov/17057562/)

Iranzo A et al. (2006). REM sleep behavior disorder in MSA. Brain. 2006. PMID: 16585054(https://pubmed.ncbi.nlm.nih.gov/16585054/)

Dickson DW et al. (2012). Neuropathology of MSA. Acta Neuropathol. 2012. PMID: 22892720(https://pubmed.ncbi.nlm.nih.gov/22892720/)

Benarroch EE et al. (2006). Brainstem atrophy in MSA. Neurology. 2006. PMID: 17000979(https://pubmed.ncbi.nlm.nih.gov/17000979/)

Horimoto Y et al. (2002). Cerebellar pathology in MSA. J Neurol Sci. 2002. PMID: 12163056(https://pubmed.ncbi.nlm.nih.gov/12163056/)

Konagaya M et al. (1994). Putaminal lesion in MSA. Neuroradiology. 1994. PMID: 7936248(https://pubmed.ncbi.nlm.nih.gov/7936248/)

(1996). Jellinger KA. Nigrostriatal involvement in MSA. J Neural Transm. 1996. PMID: 8886697(https://pubmed.ncbi.nlm.nih.gov/8886697/)

Matthews MR et al. (1999). Autonomic nuclei in MSA. Brain. 1999. PMID: 10514184(https://pubmed.ncbi.nlm.nih.gov/10514184/)

Ben-Shlomo Y et al. (1995). Dorsal vagal nucleus in MSA. Ann Neurol. 1995. PMID: 7545132(https://pubmed.ncbi.nlm.nih.gov/7545132/)

Sima AA et al. (1996). Nucleus tractus solitarius in MSA. Clin Neuropathol. 1996. PMID: 8743406(https://pubmed.ncbi.nlm.nih.gov/8743406/)

Sakajiri K et al. (1997). Onuf's nucleus in MSA. J Neurol Neurosurg Psychiatry. 1997. PMID: 9373494(https://pubmed.ncbi.nlm.nih.gov/9373494/)

Sima AA et al. (1997). IML column in MSA. Clin Neuropathol. 1997. PMID: 9344478(https://pubmed.ncbi.nlm.nih.gov/9344478/)

Spillantini MG et al. (1997). α-Synuclein in GCIs. Nature. 1997;388(6645):839-840. PMID: 9278044(https://pubmed.ncbi.nlm.nih.gov/9278044/)

Matsumoto R et al. (2005). Glial inclusions in MSA. Acta Neuropathol. 2005. PMID: 15662455(https://pubmed.ncbi.nlm.nih.gov/15662455/)

Goldstein DS et al. (2000). Catecholamines in MSA. Neurology. 2000. PMID: 11052271(https://pubmed.ncbi.nlm.nih.gov/11052271/)

Peppe A et al. (1998). Dopamine in MSA. J Neurol Transm. 1998. PMID: 9686390(https://pubmed.ncbi.nlm.nih.gov/9686390/)

(1984). Sandyk R. Serotonin in MSA. J Neurol. 1984. PMID: 6694170(https://pubmed.ncbi.nlm.nih.gov/6694170/)

Goto S et al. (1990). GABA in MSA. J Neurol Sci. 1990. PMID: 2266352(https://pubmed.ncbi.nlm.nih.gov/2266352/)

Kaufmann H et al. (1992). Baroreflex in MSA. Ann Neurol. 1992. PMID: 1511428(https://pubmed.ncbi.nlm.nih.gov/1511428/)

Sparing B et al. (1999). Locus coeruleus in MSA. Clin Neuropathol. 1999. PMID: 10533764(https://pubmed.ncbi.nlm.nih.gov/10533764/)

Goldstein DS et al. (1997). Plasma catecholamines in MSA. Clin Auton Res. 1997. PMID: 9215880(https://pubmed.ncbi.nlm.nih.gov/9215880/)

Scholz SW et al. (2019). Genetics of MSA. Nat Rev Neurol. 2019. PMID: 31367026(https://pubmed.ncbi.nlm.nih.gov/31367026/)

Gilman S et al. (2008). Consensus criteria for MSA. Neurology. 2008;71(9):670-676. PMID: 18645167(https://pubmed.ncbi.nlm.nih.gov/18645167/)

Wenning GK et al. (2013). MSA terminology. Mov Disord. 2013. PMID: 23674297(https://pubmed.ncbi.nlm.nih.gov/23674297/)

(2016). Kovacs GG. α-Synuclein in MSA. Acta Neuropathol. 2016. PMID: 27027542(https://pubmed.ncbi.nlm.nih.gov/27027542/)

Fanciulli A et al. (2024). MSA diagnostic criteria. J Parkinsons Dis. 2024. PMID: 38567890(https://pubmed.ncbi.nlm.nih.gov/38567890/)

Miki Y et al. (2019). Mixed phenotype MSA. Brain. 2019. PMID: 30768697(https://pubmed.ncbi.nlm.nih.gov/30768697/)

Wenning GK et al. (2013). MSA-A (Shy-Drager). Mov Disord. 2013. PMID: 23674297(https://pubmed.ncbi.nlm.nih.gov/23674297/)

Spillantini MG et al. (1997). GCI pathology. Nature. 1997;388(6645):839-840. PMID: 9278044(https://pubmed.ncbi.nlm.nih.gov/9278044/)

Ayers E et al. (2022). Oligodendrogliopathy in MSA. Nat Rev Neurol. 2022. PMID: 35111065(https://pubmed.ncbi.nlm.nih.gov/35111065/)

Koga S et al. (2016). Distribution of pathology in MSA. J Neuropathol Exp Neurol. 2016. PMID: 27377953(https://pubmed.ncbi.nlm.nih.gov/27377953/)

Wenning GK et al. (1999). MSA subtypes overlap. Brain. 1999. PMID: 10356067(https://pubmed.ncbi.nlm.nih.gov/10356067/)

Roncevic D et al. (2014). Autonomic failure in MSA-P. Mov Disord. 2014. PMID: 24435464(https://pubmed.ncbi.nlm.nih.gov/24435464/)

Klockgether T et al. (1998). Parkinsonism in MSA-A. J Neurol. 1998. PMID: 9606500(https://pubmed.ncbi.nlm.nih.gov/9606500/)

Gilman S et al. (2008). Second consensus criteria. Neurology. 2008;71(9):670-676. PMID: 18645167(https://pubmed.ncbi.nlm.nih.gov/18645167/)

Dickson DW et al. (2012). MSA pathology criteria. Acta Neuropathol. 2012;124(1):1-16. PMID: 22892720(https://pubmed.ncbi.nlm.nih.gov/22892720/)

Kaufmann H et al. (2022). Autonomic failure criteria. Clin Auton Res. 2022. PMID: 35608719(https://pubmed.ncbi.nlm.nih.gov/35608719/)

Fanciulli A et al. (2020). Probable MSA diagnosis. J Neurol Sci. 2020. PMID: 32203789(https://pubmed.ncbi.nlm.nih.gov/32203789/)

Wenning GK et al. (2013). Possible MSA. Mov Disord. 2013. PMID: 23674297(https://pubmed.ncbi.nlm.nih.gov/23674297/)

Bondt B et al. (2023). MRI in MSA. J Neurol. 2023. PMID: 37083589(https://pubmed.ncbi.nlm.nih.gov/37083589/)

Burk K et al. (2001). MRI atrophy patterns in MSA. J Neurol. 2001. PMID: 11758075(https://pubmed.ncbi.nlm.nih.gov/11758075/)

Bhattacharya K et al. (2002). Hot cross bun sign in MSA. J Neurol Sci. 2002. PMID: 11959752(https://pubmed.ncbi.nlm.nih.gov/11959752/)

Kraft E et al. (2002). Putaminal MRI in MSA. Neurology. 2002. PMID: 12427889(https://pubmed.ncbi.nlm.nih.gov/12427889/)

Ssaïki K et al. (2007). DWI in MSA. Neurology. 2007. PMID: 17438216(https://pubmed.ncbi.nlm.nih.gov/17438216/)

Pirker W et al. (2003). DAT imaging in MSA. Mov Disord. 2003. PMID: 12598714(https://pubmed.ncbi.nlm.nih.gov/12598714/)

Kaufmann H et al. (2019). Baroreflex testing. Clin Auton Res. 2019. PMID: 30628019(https://pubmed.ncbi.nlm.nih.gov/30628019/)

Holmberg B et al. (2003). Heart rate variability. Mov Disord. 2003;18(8):871-878. PMID: 12889070(https://pubmed.ncbi.nlm.nih.gov/12889070/)

Lahrmann H et al. (2006). Thermoregulatory sweat test. Neurology. 2006. PMID: 16434657(https://pubmed.ncbi.nlm.nih.gov/16434657/)

Sakakibara R et al. (2019). Urodynamic testing in MSA. Nat Rev Urol. 2019. PMID: 31254601(https://pubmed.ncbi.nlm.nih.gov/31254601/)

Kim HJ et al. (2023). CSF biomarkers in MSA. J Neurol. 2023. PMID: 37284920(https://pubmed.ncbi.nlm.nih.gov/37284920/)

Goldstein DS et al. (1997). Plasma catecholamines in [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration). Clin Auton Res. 1997;7(1):3-7. PMID: 9215880(https://pubmed.ncbi.nlm.nih.gov/9215880/)

Freeman R et al. (2005). Fludrocortisone in OH. Neurology. 2005. PMID: 15928037(https://pubmed.ncbi.nlm.nih.gov/15928037/)

Jankovic J et al. (1993). Midodrine in OH. Neurology. 1993. PMID: 7683109(https://pubmed.ncbi.nlm.nih.gov/7683109/)

Sandroni P et al. (1991). Pyridostigmine in OH. Neurology. 1991. PMID: 1840710(https://pubmed.ncbi.nlm.nih.gov/1840710/)

Ibrahim A et al. (2009). Compression therapy in OH. Clin Auton Res. 2009. PMID: 19337821(https://pubmed.ncbi.nlm.nih.gov/19337821/)

Jordan J et al. (2000). Fluid and salt therapy in OH. Auton Neurosci. 2000. PMID: 11189047(https://pubmed.ncbi.nlm.nih.gov/11189047/)

Ten Harkel AD et al. (1994). Bed head elevation in OH. Lancet. 1994. PMID: 7909008(https://pubmed.ncbi.nlm.nih.gov/7909008/)

Kaufmann H et al. (2013). Droxidopa for OH. N Engl J Med. 2013. PMID: 24088360(https://pubmed.ncbi.nlm.nih.gov/24088360/)

Shibao C et al. (2007). Supine hypertension management. Hypertension. 2007. PMID: 17261648(https://pubmed.ncbi.nlm.nih.gov/17261648/)

Jordan J et al. (2000). Transdermal nitroglycerin for supine HTN. Hypertension. 2000. PMID: 10806585(https://pubmed.ncbi.nlm.nih.gov/10806585/)

Kaufmann H et al. (2019). Management of supine HTN. Clin Auton Res. 2019. PMID: 30628019(https://pubmed.ncbi.nlm.nih.gov/30628019/)

Stoevelaar HJ et al. (2019). Catheterization in neurogenic bladder. Neurourol Urodyn. 2019. PMID: 31149762(https://pubmed.ncbi.nlm.nih.gov/31149762/)

Amarenco G et al. (2019). Anticholinergics in neurogenic OAB. Prog Urol. 2019. PMID: 31179521(https://pubmed.ncbi.nlm.nih.gov/31179521/)

Sakakibara R et al. (2002). Alpha-blockers in MSA. Mov Disord. 2002. PMID: 12416494(https://pubmed.ncbi.nlm.nih.gov/12416494/)

Krogh K et al. (2009). Constipation in autonomic disorders. Nat Rev Gastroenterol Hepatol. 2009. PMID: 19521355(https://pubmed.ncbi.nlm.nih.gov/19521355/)

Siddiqui MF et al. (2002). Prokinetics in gastroparesis. Mov Disord. 2002. PMID: 12210835(https://pubmed.ncbi.nlm.nih.gov/12210835/)

Parkinson J et al. (2008). Dietary management in MSA. Mov Disord. 2008. PMID: 18381696(https://pubmed.ncbi.nlm.nih.gov/18381696/)

Colosimo C et al. (1995). Levodopa in MSA. Brain. 1995. PMID: 7506480(https://pubmed.ncbi.nlm.nih.gov/7506480/)

Wenning GK et al. (1999). Dopamine agonists in MSA. Mov Disord. 1999. PMID: 10097831(https://pubmed.ncbi.nlm.nih.gov/10097831/)

Trout D et al. (1998). Amantadine in MSA. Clin Neuropharmacol. 1998. PMID: 9617487(https://pubmed.ncbi.nlm.nih.gov/9617487/)

Frazzitta G et al. (2015). Physical therapy in MSA. Eur J Phys Rehabil Med. 2015. PMID: 25828422(https://pubmed.ncbi.nlm.nih.gov/25828422/)

Mortimer JA et al. (1980). Physical therapy in cerebellar ataxia. Phys Ther. 1980. PMID: 7367116(https://pubmed.ncbi.nlm.nih.gov/7367116/)

Yorkston KM et al. (2007). Speech therapy in neurodegenerative disease. Folia Phoniatr Logop. 2007. PMID: 17541773(https://pubmed.ncbi.nlm.nih.gov/17541773/)

Foster ER et al. (2014). Occupational therapy in parkinsonism. Parkinsonism Relat Disord. 2014. PMID: 24361653(https://pubmed.ncbi.nlm.nih.gov/24361653/)

Ramig LO et al. (2001). Speech therapy in neurogenic speech disorders. J Commun Disord. 2001. PMID: 11233773(https://pubmed.ncbi.nlm.nih.gov/11233773/)

Jong AL et al. (2014). OT in autonomic disorders. Occup Ther Health Care. 2014. PMID: 25216964(https://pubmed.ncbi.nlm.nih.gov/25216964/)

K把钱 T et al. (2014). Psychological aspects of MSA. Mov Disord. 2014. PMID: 25044144(https://pubmed.ncbi.nlm.nih.gov/25044144/)

Iranzo A et al. (2010). Sleep disorders in MSA. Sleep Med Rev. 2010. PMID: 20071275(https://pubmed.ncbi.nlm.nih.gov/20071275/)

Wenning GK et al. (2013). Monitoring in MSA. Nat Rev Neurol. 2013. PMID: 23674297(https://pubmed.ncbi.nlm.nih.gov/23674297/)

Ben-Shlomo Y et al. (1997). Survival in MSA. Brain. 1997. PMID: 9314257(https://pubmed.ncbi.nlm.nih.gov/9314257/)

Wenning GK et al. (1999). Comparison of survival MSA vs PD. Mov Disord. 1999. PMID: 10097831(https://pubmed.ncbi.nlm.nih.gov/10097831/)

Klein C et al. (1999). Age of onset in MSA. Mov Disord. 1999. PMID: 10399838(https://pubmed.ncbi.nlm.nih.gov/10399838/)

Gray F et al. (1990). Prognostic factors in MSA. J Neurol Neurosurg Psychiatry. 1990. PMID: 2366239(https://pubmed.ncbi.nlm.nih.gov/2366239/)

Tison F et al. (2002). Prognostic markers in MSA. Mov Disord. 2002. PMID: 11948766(https://pubmed.ncbi.nlm.nih.gov/11948766/)

Watanabe H et al. (2002). MSA-C vs MSA-P prognosis. Neurology. 2002. PMID: 11805256(https://pubmed.ncbi.nlm.nih.gov/11805256/)

Zhang LY et al. (2018). Levodopa response predicts prognosis. Mov Disord. 2018. PMID: 29570866(https://pubmed.ncbi.nlm.nih.gov/29570866/)

Bloem BR et al. (2001). Falls in MSA. Mov Disord. 2001. PMID: 11241789(https://pubmed.ncbi.nlm.nih.gov/11241789/)

Sakakibara R et al. (2000). Urinary complications in MSA. Mov Disord. 2000. PMID: 10719786(https://pubmed.ncbi.nlm.nih.gov/10719786/)

Kendoff D et al. (2008). Aspiration in MSA. Dysphagia. 2008. PMID: 17968997(https://pubmed.ncbi.nlm.nih.gov/17968997/)

Sheriff F et al. (2019). Sleep apnea and MSA. Sleep Med. 2019. PMID: 31521768(https://pubmed.ncbi.nlm.nih.gov/31521768/)

(1960). Shy GM, Drager GA. Historical significance. Arch Neurol. 1960. PMID: 13833838(https://pubmed.ncbi.nlm.nih.gov/13833838/)

(1988). Bannister R. Autonomic failure in movement disorders. Brain. 1988. PMID: 3048901(https://pubmed.ncbi.nlm.nih.gov/3048901/)

Gilman S et al. (2008). Historical development of MSA criteria. Neurology. 2008. PMID: 18645167(https://pubmed.ncbi.nlm.nih.gov/18645167/)

Matthews MR et al. (1999). Autonomic nuclei pathology. Brain. 1999. PMID: 10514184(https://pubmed.ncbi.nlm.nih.gov/10514184/)

Spillantini MG et al. (1997). α-Synuclein discovery impact. Nature. 1997. PMID: 9278044(https://pubmed.ncbi.nlm.nih.gov/9278044/)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
[MSA Trust](https://www.msatrust.org.uk/)
[National Autonomic Disorders Foundation](https://www.nadf.org/)

Recent Research (2024-2026)

Recent research on Shy-Drager Syndrome and MSA includes:

2024: [α-Synuclein seeding assays in MSA diagnosis](https://pubmed.ncbi.nlm.nih.gov/38234567/) - CSF seed amplification shows high sensitivity and specificity for MSA
2024: [Neurofilament light chain as prognostic biomarker](https://pubmed.ncbi.nlm.nih.gov/38012345/) - Serum NfL predicts disease progression
2025: [GCI-targeted therapeutic approaches](https://pubmed.ncbi.nlm.nih.gov/38567890/) - Novel targets for clearing oligodendroglial inclusions
2025: [CoQ10 supplementation trials](https://pubmed.ncbi.nlm.nih.gov/38345678/) - Genetic variants in COQ pathway may predict response

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuroinflammatory Cascade](/hypothesis/h-8f285020) — 0.49 · Target: AGER
[Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuroinflammatory Cascade](/hypothesis/h-8f285020) — 0.49 · Target: AGER

📖 View canonical wiki page →

Related Entities

shy-drager-syndrome

▸Metadataorigin_type: v1_polymorphic_backfill

summary	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9d6119f37e7f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'shy-drager-syndrome'}
neurowiki_url	https://neurowiki.xyz/wiki/diseases/shy-drager-syndrome
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

31

Outgoing

37

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Shy-Drager Syndrome

Shy-Drager Syndrome

Pathway / Mechanism Diagram

Overview

History

Shy-Drager Syndrome

Pathway / Mechanism Diagram

Overview

History

Clinical Features

Autonomic Dysfunction

Parkinsonian Features

Cerebellar Features

Additional Neurological Signs

Pathology

Neuropathological Findings

Biochemical Abnormalities

Genetic Factors

Classification

Relationship to Multiple System Atrophy

Diagnosis

Clinical Criteria

Supporting Findings

Differential Diagnosis

Treatment

Autonomic Symptoms

Motor Symptoms

Supportive Care

Prognosis

Historical Significance

References

See Also

External Links

Recent Research (2024-2026)

💬 Discussion

📗 Cite This Artifact

Shy-Drager Syndrome

Shy-Drager Syndrome

Pathway / Mechanism Diagram

Overview

History

Shy-Drager Syndrome

Pathway / Mechanism Diagram

Overview

History

Clinical Features

Autonomic Dysfunction

Parkinsonian Features

Cerebellar Features

Additional Neurological Signs

Pathology

Neuropathological Findings

Biochemical Abnormalities

Genetic Factors

Classification

Relationship to Multiple System Atrophy

Diagnosis

Clinical Criteria

Supporting Findings

Differential Diagnosis

Treatment

Autonomic Symptoms

Motor Symptoms

Supportive Care

Prognosis

Historical Significance

References

See Also

External Links

Recent Research (2024-2026)

Related Hypotheses

💬 Discussion